You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 15, 2025

CLINICAL TRIALS PROFILE FOR VESICARE LS


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Vesicare Ls

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00333112 ↗ A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men. Completed Astellas Pharma Inc Phase 4 2006-05-01 A study to evaluate solifenacin succinate in combination with tamsulosin for the treatment of residual OAB symptoms in men.
NCT00368706 ↗ A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients Completed Astellas Pharma Inc Phase 3 2006-09-01 To evaluate the efficacy and safety of solifenacin succinate (Vesicare) 5mg OD in subjects with overactive bladder compared to tolterodine wmg, bid
NCT00431041 ↗ Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR) Completed Astellas Pharma Canada, Inc. Phase 4 2006-12-01 The purpose of this study is to compare the safety and efficacy of solifenacin with oxybutynin immediate-release (IR) for the treatment of overactive bladder (OAB).
NCT00431041 ↗ Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR) Completed Astellas Pharma Inc Phase 4 2006-12-01 The purpose of this study is to compare the safety and efficacy of solifenacin with oxybutynin immediate-release (IR) for the treatment of overactive bladder (OAB).
NCT00454740 ↗ Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder Completed Astellas Pharma Inc Phase 3 2004-06-01 To evaluate the efficacy of 5 and10mg solifenacin succinate in patients with urgency who have OAB syndrome (urgency, with or without urge incontinence, usually with frequency and nocturia) and wish to switch from tolterodine tartrate extended release to solifenacin succinate due to lack of sufficient improvement in urgency episodes
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Vesicare Ls

Condition Name

Condition Name for Vesicare Ls
Intervention Trials
Overactive Bladder 24
Urinary Bladder, Overactive 15
Urinary Incontinence 6
Urologic Diseases 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Vesicare Ls
Intervention Trials
Urinary Bladder, Overactive 45
Enuresis 10
Urinary Incontinence 10
Urinary Incontinence, Urge 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Vesicare Ls

Trials by Country

Trials by Country for Vesicare Ls
Location Trials
United States 330
Canada 31
Germany 18
Hungary 15
United Kingdom 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Vesicare Ls
Location Trials
California 15
Texas 13
Pennsylvania 13
Florida 13
North Carolina 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Vesicare Ls

Clinical Trial Phase

Clinical Trial Phase for Vesicare Ls
Clinical Trial Phase Trials
Phase 4 27
Phase 3 15
Phase 2/Phase 3 1
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Vesicare Ls
Clinical Trial Phase Trials
Completed 50
Terminated 7
Unknown status 5
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Vesicare Ls

Sponsor Name

Sponsor Name for Vesicare Ls
Sponsor Trials
Astellas Pharma Inc 25
Astellas Pharma Europe B.V. 8
Astellas Pharma Korea, Inc. 6
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Vesicare Ls
Sponsor Trials
Industry 52
Other 49
NIH 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

VESIcare LS: Clinical Trials, Market Analysis, and Projections

Introduction to VESIcare LS

VESIcare LS, an oral suspension of solifenacin succinate, is a muscarinic antagonist approved by the FDA for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients aged 2 years and older. This approval marks a significant milestone in the management of bladder dysfunction in young patients.

Clinical Trials Overview

The efficacy of VESIcare LS was established through two clinical trials involving a total of 95 pediatric patients with NDO, aged 2 to 17 years[1][4].

Trial Design and Outcomes

  • Patient Groups: The trials included two age groups: patients aged 2 to less than 5 years and those aged 5 to 17 years.
  • Primary Efficacy Endpoint: The primary goal was to measure the maximum amount of urine the bladder could hold after 24 weeks of treatment.
  • Results:
    • In the first study, 17 patients aged 2 to less than 5 years showed an average increase of 39 mL in bladder capacity.
    • In the second study, 49 patients aged 5 to 17 years demonstrated an average increase of 57 mL in bladder capacity[1][4].
  • Additional Benefits: Both studies observed reductions in bladder pressure, spontaneous bladder contractions, and the number of incontinence episodes.

Dosage and Administration

The dosing of VESIcare LS is weight-based and administered once daily. Here are the recommended starting and maximum doses:

Weight Range Starting Dose Maximum Dose
9 kg to 15 kg 2 mL 4 mL
> 15 kg to 30 kg 3 mL 5 mL
> 30 kg to 45 kg 3 mL 6 mL
> 45 kg to 60 kg 4 mL 8 mL
> 60 kg 5 mL 10 mL

Patients should take VESIcare LS orally followed by a liquid, such as water or milk[2].

Safety and Contraindications

Urinary Retention

The use of VESIcare LS in patients with clinically significant bladder outlet obstruction may result in urinary retention. It is not recommended in such patients without clean intermittent catheterization[2].

Gastrointestinal Disorders

VESIcare LS is contraindicated in patients with gastric retention and not recommended in those with conditions associated with decreased gastrointestinal motility due to the risk of further decreased motility[2].

Market Analysis

Market Growth

The solifenacin succinate market, including VESIcare LS, is projected to grow significantly. According to market forecasts, this segment is expected to experience a Compound Annual Growth Rate (CAGR) of 50.90% from 2024 to 2031[5].

Patent and Clinical Trial Landscape

  • Patents: VESIcare LS has a robust patent profile with 23 international patents and 1 US patent.
  • Clinical Trials: There have been numerous clinical trials, with 67 trials listed, indicating ongoing research and development in this area[5].

Market Competition

The approval of VESIcare LS for pediatric use opens up a new market segment, but it also faces competition from other antimuscarinic drugs. However, its unique formulation as an oral suspension makes it particularly suitable for pediatric patients, giving it a competitive edge.

Projections and Future Outlook

Market Expansion

Given the significant growth projected for the solifenacin succinate market, VESIcare LS is poised to capture a substantial share. The drug's approval for pediatric use expands its market potential beyond adult patients with overactive bladder.

Ongoing Research

Recent clinical trials, including Phase 1 and Phase 4 studies, indicate continued research efforts to further establish the safety and efficacy of VESIcare LS. This ongoing research may lead to additional approvals or new indications, further boosting market growth[5].

Key Takeaways

  • Clinical Efficacy: VESIcare LS has demonstrated significant efficacy in increasing bladder capacity and reducing incontinence episodes in pediatric patients with NDO.
  • Market Growth: The market for solifenacin succinate, including VESIcare LS, is expected to grow at a CAGR of 50.90% from 2024 to 2031.
  • Safety Considerations: The drug has specific contraindications and precautions, particularly regarding urinary retention and gastrointestinal disorders.
  • Ongoing Research: Continued clinical trials and research efforts are expected to further solidify VESIcare LS's position in the market.

FAQs

What is VESIcare LS used for?

VESIcare LS is used for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients aged 2 years and older.

How is VESIcare LS administered?

VESIcare LS is administered orally as a suspension, once daily, with the dose based on the patient's weight.

What were the key findings from the clinical trials?

The clinical trials showed significant increases in bladder capacity and reductions in bladder pressure, spontaneous bladder contractions, and incontinence episodes.

What are the contraindications for VESIcare LS?

VESIcare LS is contraindicated in patients with gastric retention and not recommended in those with clinically significant bladder outlet obstruction or conditions associated with decreased gastrointestinal motility.

What is the projected market growth for VESIcare LS?

The market for solifenacin succinate, including VESIcare LS, is expected to grow at a CAGR of 50.90% from 2024 to 2031.

Sources

  1. FDA Approves VESIcare for Pediatric Use - Contemporary Pediatrics
  2. VESIcare LS: Package Insert / Prescribing Information - Drugs.com
  3. Summary Basis of Decision for Vesicare - Health Products and Food Branch
  4. FDA Approves First Treatment for a Form of Bladder Dysfunction in Pediatric Patients - FDA
  5. VESICARE LS Drug Patent Profile - DrugPatentWatch

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.